Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM
Conditions: Multiple Myeloma; Cytokine Release Syndrome; Refractory Multiple Myeloma; Immune Effector Cell Associated Neurotoxicity Syndrome Interventions: Drug: Siltuximab Sponsors: Case Comprehensive Cancer Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 8, 2024 Category: Research Source Type: clinical trials
Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
TARRYTOWN, N.Y., April 07, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the oral plenary session presentation of positive pivotal data from the Phase 1/2 LINKER-MM1 trial of linvoseltamab in patients with... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 7, 2024 Category: Pharmaceuticals Source Type: clinical trials
Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
Conditions: Multiple Myeloma; Refractory Multiple Myeloma; Relapsed Multiple Myeloma Interventions: Biological: Talquetamab; Drug: Iberdomide; Drug: Dexamethasone; Procedure: Bone Marrow Biopsy Sponsors: Thomas Martin, MD; Bristol-Myers Squibb; Janssen Research& Development, LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 4, 2024 Category: Research Source Type: clinical trials
Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation
Conditions: Newly Diagnosed Multiple Myeloma; Multiple Myeloma; Autologous Stem Cell Transplantation Interventions: Biological: Daratumumab; Drug: Lenalidomide; Drug: Bortezomib; Drug: Dexamethasone Sponsors: UNC Lineberger Comprehensive Cancer Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 4, 2024 Category: Research Source Type: clinical trials
Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)
Conditions: Cholangiocarcinoma; Multiple Myeloma; Colon Cancer; Rectal Cancer Interventions: Other: Return of Genetic Results: Biomarker information from cancer cells; Other: Return of Genetic Results: Inherited mutations related to cancer; Other: Return of Genetic Results: Inherited mutations related to other medical issues Sponsors: Washington University School of Medicine; National Cancer Institute (NCI); The Foundation for Barnes-Jewish Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 1, 2024 Category: Research Source Type: clinical trials
Precision Medicine Study
Conditions: Multiple Myeloma Sponsors: Icahn School of Medicine at Mount Sinai; National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 29, 2024 Category: Research Source Type: clinical trials
Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCL
Conditions: Multiple Myeloma; Primary Plasma Cell Leukemia Interventions: Biological: CT071 Sponsors: CARsgen Therapeutics Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 27, 2024 Category: Research Source Type: clinical trials
Chaplain-Delivered Compassion Meditation to Improve Spiritual Care of Patients Receiving Stem Cell Transplantation
Conditions: Lymphoma; Multiple Myeloma Interventions: Procedure: Spiritual Therapy; Other: Best Practice Sponsors: Emory University; National Cancer Institute (NCI); National Center for Complementary and Integrative Health (NCCIH) Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 25, 2024 Category: Research Source Type: clinical trials
Study on the Efficacy and Safety of Low-dose CTX as Maintenance Therapy for MM Unsuitable for Transplantation
Conditions: Newly Diagnosed Multiple Myeloma Interventions: Drug: Cyclophosphamide; Drug: Lenalidomide Sponsors: Jinling Hospital, China Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 21, 2024 Category: Research Source Type: clinical trials
PatIent exPeRiences and prEFerence of trEatment foR Multiple Myeloma
Conditions: Multiple Myeloma Interventions: Other: Patient Interview Sponsors: The Christie NHS Foundation Trust; CellCentric Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 21, 2024 Category: Research Source Type: clinical trials
Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia
Conditions: Diffuse Large B Cell Lymphoma; Multiple Myeloma Interventions: Diagnostic Test: PointCheck Sponsors: Leuko Labs, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 21, 2024 Category: Research Source Type: clinical trials
Narlumosbart Compared With Denosumab in Patients With Multiple Myeloma Bone Disease
Conditions: Multiple Myeloma; Bone Diseases Interventions: Drug: Narlumosbart; Drug: Denosumab Sponsors: RenJi Hospital; Shanghai JMT-Bio Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 18, 2024 Category: Research Source Type: clinical trials
Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1)
Conditions: Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Multiple Myeloma Interventions: Procedure: Biopsy; Procedure: Biospecimen Collection; Procedure: Computed Tomography; Drug: Erdafitinib; Procedure: Magnetic Resonance Imaging Sponsors: National Cancer Institute (NCI) Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 13, 2024 Category: Research Source Type: clinical trials
Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)
Conditions: Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Hematopoietic and Lymphoid Cell Neoplasm; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Multiple Myeloma Interventions: Procedure: Biopsy; Procedure: Biospecimen Collection; Procedure: Echocardiography; Procedure: Multigated Acquisition Scan; Drug: Osimertinib; Procedure: Radiologic Examination Sponsors: National Cancer Institute (NCI) Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 11, 2024 Category: Research Source Type: clinical trials
Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma
Conditions: Refractory Multiple Myeloma; Relapsed Multiple Myeloma Interventions: Drug: Descartes-15 Sponsors: Cartesian Therapeutics Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 11, 2024 Category: Research Source Type: clinical trials
